These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 18977255

  • 1. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC.
    J Control Release; 2009 Feb 10; 133(3):172-7. PubMed ID: 18977255
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
    Youn YS, Jeon JE, Chae SY, Lee S, Lee KC.
    Diabetes Obes Metab; 2008 Apr 10; 10(4):343-6. PubMed ID: 18034839
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
    Baggio LL, Huang Q, Cao X, Drucker DJ.
    Gastroenterology; 2008 Apr 10; 134(4):1137-47. PubMed ID: 18313669
    [Abstract] [Full Text] [Related]

  • 9. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R, Yano T, Ogawa J, Tanaka N, Toda N, Yoshida M, Takano R, Inoue M, Honda T, Kume S, Matsumoto K.
    Eur J Pharmacol; 2014 Aug 15; 737():194-201. PubMed ID: 24858371
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
    Chae SY, Jin CH, Shin JH, Son S, Kim TH, Lee S, Youn YS, Byun Y, Lee MS, Lee KC.
    J Control Release; 2010 Mar 03; 142(2):206-13. PubMed ID: 19900495
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
    Dhanesha N, Joharapurkar A, Shah G, Dhote V, Kshirsagar S, Bahekar R, Jain M.
    J Diabetes; 2012 Dec 03; 4(4):369-77. PubMed ID: 22356440
    [Abstract] [Full Text] [Related]

  • 16. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
    Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G, Zhang R, Zhang S, Lin L, Chen K, Xie X, Nan F, Young AA, Wang MW.
    Proc Natl Acad Sci U S A; 2007 Jan 16; 104(3):943-8. PubMed ID: 17213311
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Exendin-4 and exercise promotes beta-cell function and mass through IRS2 induction in islets of diabetic rats.
    Park S, Hong SM, Sung SR.
    Life Sci; 2008 Feb 27; 82(9-10):503-11. PubMed ID: 18237751
    [Abstract] [Full Text] [Related]

  • 20. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
    Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M.
    Diabetes; 1999 May 27; 48(5):1026-34. PubMed ID: 10331407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.